Published in final edited form as:

Org Lett. 2007 August 30; 9(18): 3547–3550. doi:10.1021/ol7014219.

Stereo- and Regioselective Glycosylations To the Bis-C-arylglucoside of Kidamycin

ZhongBo Fei and Frank E. McDonald

Department of Chemistry, Emory University, Atlanta, GA 30322

Frank E. McDonald: fmcdona@emory.edu

Abstract

In explorations towards the total synthesis of the antitumor anthrapyran natural product kidamycin, the regioselective introduction of aminosugars angolosamine and vancosamine as C-arylglucosides has been accomplished onto hydroxylated anthrapyran aglycones. Specifically, the 9,11-dihydroxylated anthrapyran A undergoes sequential glycosylations with angolosamine synthon B and vancosamine synthon C to regio- and stereoselectively afford bis-C-glycoside D corresponding to the C-glycoside pattern of kidamycin.

The pluramycins are a relatively large family of antitumor antibiotic natural products containing the 4*H*-anthra[1,2-*b*]pyran-4,7,12-trione substructure, with variations in the side chain and substitution patterns of carbohydrates on the anthrapyran core aglycone.¹ Kidamycin was isolated from *Streptomyces* soil bacteria in the early 1970s, as one of the earliest known members of the pluramycin antibiotics.² Kidamycin demonstrates a wide spectrum of antimicrobial activity against anaerobic bacteria, aerobic and facultative bacteria and yeasts,³ and also has antitumor and cytotoxic properties against leukemia L-1210 as well as life-prolongation activity on mice bearing ascites tumors at single i.p. doses from just below the LD₅₀ (18 mg/kg) to 1/16 of the LD₅₀.⁴ The structure and conformation of kidamycin (**1**, Figure 1) was determined by NMR and X-ray crystallographic studies, exhibiting a novel *meta*-arrangement of two different C-arylglucosidic aminosugars, with equatorially- substituted angolosamine at C8 and axially- substituted vancosamine at C10.⁵ In the course of characterization studies, the acid-sensitivity of the axial C-glycoside to anomerization was discovered to favor equatorially- substituted vancosamine in isokidamycin (**2**), which is attributed to occur by protonation of

Correspondence to: Frank E. McDonald, fmcdona@emory.edu.

Supporting Information **Available:** Experimental procedures and characterization data for new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

the pyranose oxygen and elimination to a quinomethide intermediate, followed by reclosure of the pyran ring.^{5a} Despite the interesting biological activity of kidamycin, this structurally complex compound has to date resisted total synthesis. Two syntheses of the kidamycin aglycone have been recorded,^{6,7} as well as the development of several methods for the regioselective construction of *meta*-bis-*C*-aryl glycosides.⁸ In this report we will disclose the first cases in which the angolosamine and vancosamine sugars have been stereo- and regioselectively introduced onto an aglycone bearing most of the features of the natural product kidamycin. Our synthetic strategy features late-stage sequential *C*-glycosylation at C8 of kidamycin aglycone or related anthrapyran synthon with suitably protected angolosamine synthon, and at C10 with vancosamine synthon.

Both carbohydrate components leading to angolosamine and vancosamine were prepared utilizing tungsten-catalyzed alkynol cycloisomerization to form pyranosyl glycal intermediates. For *D*-angolosamine synthon **6** (Scheme 1), cycloisomerization⁹ of alkynyl alcohol **3** provided glycal **4**.¹⁰ Removal of the silyl ether protective group allowed direct S_N2 substitution¹¹ to introduce an azide group with inversion of stereochemistry to produce **5**, with non-basic nitrogen in the azide functional group.¹² Treatment of this glycal **5** with hot aqueous acid¹³ effected one-pot hydrolysis of vinyl ether and cleavage of MOM ether to produce the diol, which was acylated to generate **6** as the angolosamine glycosyl donor. Likewise, the synthesis of *L*-vancosamine synthon **10** began with alkynol cycloisomerization of **7** to **8**.^{10,14} *N*-Methylation of **8** was complicated by formation of bicyclic carbamate **9**,¹⁵ which could be prevented by using exactly one equivalent of base. However, we recognized the advantages of the cyclic carbamate in avoiding carbonyl-group participation of the acyclic Cbz group in glycosylations as well as the convex nature of compound **9** in stereoselective glycosylation, and were able to optimize preparation of **9** by using excess base until complete conversion to the cyclic carbamate had occurred, followed by addition of iodomethane. Further derivatization of glycal **9** to glycosyl acetate **10**¹⁶ broadened the choice of conditions for glycosylations.

In 2005 we reported the synthesis of kidamycin aglycone via the advanced intermediate **11**.⁷ Friedel-Crafts-type glycosylation¹⁷ of **11** with angolosamine synthon **5** stereo- and regioselectively provided C8-glycoside **13**, albeit with low conversion (Scheme 2). Similar results were observed with the C12-thioethyl analog **12**. The regioselectivity of these glycosylations was assigned by the disappearance of the C8 hydrogen resonance in comparing ¹H NMR spectra for compounds **11** -**14** and confirmed by the observation of a nuclear Overhauser effect between H7 and the anomeric hydrogen H1' in compound **14**.¹⁸ This glycosylation was not further optimized after we found that the *O*-methyl groups could not be removed from the aglycone nucleus in the presence of the fragile benzylic carbon-oxygen bond of the angolosamine carbohydrate, but we did demonstrate reduction of the azide of **13** to amine which was characterized as peracetylated **15**.

Introduction of vancosamine was also explored with several substrates, with C11 phenol **16** as a representative example (Scheme 2).^{19,20} Initial results in SnCl₄-promoted glycosylation with vancosamine synthon **10** provided a mixture of C10-glycoside anomers **17** and **18**,¹⁸ with the formation of equatorially-substituted **18** attributed to Lewis acid-catalyzed anomerization in a mechanism analogous to that proposed for the isomerization of

kidamycin (**1**) to isokidamycin (**2**). The positional selectivity for this glycosylation at C10 was evident by the disappearance of the C10 hydrogen resonance in the formation of compounds **17** and **18**, and the anomeric stereochemistry was assigned in analogy with kidamycin (**1**) and isokidamycin (**2**), with the anomeric ^1H resonance of δ 5.48 for **17** consistent with a pseudoequatorial hydrogen, relative to the shielded pseudoaxial anomeric hydrogen of **18** at δ 5.09. Lowering the reaction temperature increased stereoselectivity as well as the isolated yield for production of **17**,²¹ but under these conditions we also observed formation of the *para*-C8-glycoside isomer **19**, characterized by the absence of the C8 hydrogen and presence of C10 hydrogen in comparison with compounds **16-18**.¹⁸

At this stage, we modified our aglycone synthesis to introduce an additional hydroxyl substituent at C9, which might be advantageous in more easily forming *C*-glycosides at C8 as well as C10. *Ortho*-lithiation²² of amide **21** and addition to the aldehyde **22**, followed by desilylation provided the lactone **23**. The phenol of **23** underwent addition-elimination²³ with *beta*-chlorodienoate (**24**)^{7,24} to form compound **25**, although forcing conditions were required as phenolate reactivity was diminished due to conjugation with the ester carbonyl. Hydrogenolysis of the doubly benzylic C7 lactone¹⁸ also resulted in removal of the isopropyl ethers, but global *O*-benzylation of both phenols and the carboxylic acid provided **26**, which was easily purified. After saponification of both esters to dicarboxylic acid **27**, double Friedel-Crafts cyclization²⁵ provided the anthrapyran **28**, which was converted into a variety of *O*-protected congeners **29 - 31** (Scheme 3).

Glycosylation was first conducted with the bromoethyl ether-protected **30** bearing a single phenol at C9, which was anticipated to direct *ortho*-*C*-glycosylation²⁶ at both C8 and C10. Introduction of angolosamine synthon **6** proceeded in good yield and with apparent complete stereo- and regioselectivity for C8-glycosylation^{17,18} in product **32** (Scheme 4). However, the attempted introduction of vancosamine via the C9-hydroxyl group instead provided the surprising result of C7-glycosylation to provide the anthrone **33**, which was characterized by observation of ^1H - ^1H coupling between the C7 hydrogen and the anomeric hydrogen of the vancosamine unit,¹⁸ as well as the white color of product **33**, consistent with interruption of conjugation in the C ring at C7. Thus the aglycone substrate **31** without protective groups at either C9 or C11 phenols was subjected to glycosylation with angolosamine donor **6**, providing C8-glycoside **34** in good yield, which in turn underwent regio- and stereoselective glycosylation with vancosamine synthon **10** to provide the C10-glycoside **35**,¹⁸ possessing a *meta*-bisglycosylated anthrapyran with considerable structural similarity to kidamycin (**1**).

Although we have not yet completed the synthesis of kidamycin, we have demonstrated a number of interesting and informative glycosylation transformations which have culminated in the successful preparation of the bis-*C*-aryl glycoside **35** closely corresponding to most of the structural features of kidamycin. Continuing efforts will focus on completing the total synthesis from either the doubly glycosylated intermediate **35** or, less aggressively, by removing the C9 oxygen from intermediate **34** prior to the second glycosylation to introduce the *C*-vancosamine glycoside.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by the National Institutes of Health (R01 CA59703). We also acknowledge use of shared instrumentation provided by grants from the National Institutes of Health, National Science Foundation, and the Georgia Research Alliance (NMR spectroscopy, mass spectrometry), as well as the University Research Committee of Emory University (polarimeter).

References

1. (a) Berdy J. *Adv Appl Microbiol.* 1974; 18:309. [PubMed: 4613148] (b) Séquin U. *Prog Chem Org Nat Prod.* 1986; 50:57.(c) Rohr J, Thiericke R. *Nat Prod Rep.* 1992:103. [PubMed: 1620493] (d) Hansen MR, Hurley LH. *Acc Chem Res.* 1996; 29:249.
2. Kanda N. *J Antibiot.* 1971; 24:599. [PubMed: 5132247]
3. Kanda N. *J Antibiot.* 1972; 25:557. [PubMed: 4648310]
4. Kanda N, Kono M, Asano K. *J Antibiot.* 1972; 25:553. [PubMed: 4648309]
5. (a) Furukawa M, Iitaka Y. *Tetrahedron Lett.* 1974; 15:3287.(b) Furukawa M, Hayakawa I, Ohta G, Iitaka Y. *Tetrahedron.* 1975; 31:2989.
6. Hauser FM, Rhee RP. *J Org Chem.* 1980; 45:3061.
7. Fei Z, McDonald FE. *Org Lett.* 2005; 7:3617. [PubMed: 16092833]
8. (a) Dubois E, Beau JM. *Carbohydr Res.* 1992; 228:103. [PubMed: 1516081] (b) Parker KA, Koh Yh. *J Am Chem Soc.* 1994; 116:11149.(c) Kaelin DE, Lopez OD, Martin SF. *J Am Chem Soc.* 2001; 123:6937. [PubMed: 11448205] (d) Kaelin DE, Sparks SM, Plake HR, Martin SF. *J Am Chem Soc.* 2003; 125:12994. [PubMed: 14570450] (e) Yamauchi T, Watanabe Y, Suzuki K, Matsumoto T. *Synthesis.* 2006:2818.
9. (a) McDonald FE, Reddy KS, Díaz Y. *J Am Chem Soc.* 2000; 122:4304.(b) Koo B, McDonald FE. *Org Lett.* 2007; 9:1737. [PubMed: 17385878]
10. See Supporting Information for details on the preparation of alkynyl alcohols **3** and **7**.
11. Thompson AS, Humphrey GR, DeMarco AM, Mathre DJ, Grabowski EJJ. *J Org Chem.* 1993; 58:5886.
12. Parker KA, Ding Qj. *Tetrahedron.* 2000; 56:10255.
13. Meyers AI, Durandetta JL, Munavu R. *J Org Chem.* 1975; 40:2025.
14. Cutchins WW, McDonald FE. *Org Lett.* 2002; 4:749. [PubMed: 11869118]
15. Parker KA, Chang W. *Org Lett.* 2003; 5:3891. [PubMed: 14535736]
16. Lam SN, Gervay-Hague J. *Org Lett.* 2003; 5:4219. [PubMed: 14572289]
17. (a) Matsumoto T, Katsuki M, Suzuki K. *Tetrahedron Lett.* 1989; 30:833.(b) Kuribayashi T, Ohkawa N, Satoh S. *Tetrahedron Letters.* 1998; 39:4537.(c) Kuribayashi T, Ohkawa N, Satoh S. *Tetrahedron Lett.* 1998; 39:4541.(d) Shuto S, Horne G, Marwood RD, Potter BVL. *Chem Eur J.* 2001; 7:4937. [PubMed: 11763462]
18. See Supporting Information for more details on the positional and stereochemical assignments for C-glycosylation products.
19. Compound **12** arose from an unsuccessful attempt to remove methyl ethers from **11** with AlCl₃ / EtSH (ref. 20).
20. Node M, Nishide K, Fuji K, Fujita E. *J Org Chem.* 1980; 45:4275.
21. The C-vancosamine glycosylation product **17** undergoes partial anomerization to a mixture of **17** and **18** upon the prolonged reaction time or higher temperature required for complete conversion of starting materials.
22. Falk H, Mayr E. *Monatsh Chem.* 1995; 126:699.
23. (a) Hormi OEO. *J Org Chem.* 1988; 53:880.(b) Hormi OEO, Hirvela L. *Tetrahedron Lett.* 1993; 34:6463.

24. Andrews JFP, Regan AC. Tetrahedron Lett. 1991; 32:7731.
25. (a) Bycroft BW, Roberts JCJ. Chem Soc. 1963:4868.(b) Devos A, Frisque-Hesbain AM, Colens A, Ghosez L. J Chem Soc, chem Commun. 1979:1180.
26. (a) Matsumoto T, Maeta H, Suzuki K, Tsuchihashi Gi. Tetrahedron Lett. 1988; 29:3567.(b) Matsumoto T, Katsuki M, Suzuki K. Tetrahedron Lett. 1988; 29:6935.(c) Matsumoto T, Hosoya T, Suzuki K. Tetrahedron Lett. 1990; 31:4629.(d) Ben A, Yamauchi T, Matsumoto T, Suzuki K. Synlett. 2004:225.

Figure 1. Structures of kidamycin and isokidamycin

Scheme 1. Syntheses of glycosyl donors 6 and 10 via alkynol cycloisomerization

Scheme 2. Glycosylations of anthrapyrans 11, 12, and 16

Scheme 3. Synthesis of anthrapyrans bearing 9-hydroxyl substituent

Scheme 4. Bis-glycosylations of 9-hydroxyl-substituted anthracyclins 30 and 31